CMV Infection
32
5
5
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.3%
2 terminated out of 32 trials
83.3%
-3.2% vs benchmark
19%
6 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (32)
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Study Evaluating the Efficacy and Safety of Artesunate
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial
Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA